Trump pulls FDA nominee amid pro-life questions

5 hours ago 83

WASHINGTON, D.C. (LifeSiteNews) – The Trump administration confirmed on Tuesday that it has withdrawn the nomination of administration health policy adviser Dr. Heidi Overton to succeed Marty Makary as Commissioner of the U.S. Food and Drug Administration (FDA), a position that has lacked a permanent holder since May.

Earlier this year, the White House confirmed Makary’s resignation amid a storm of issues with his tenure, including his handling of abortion pills and vaccines as well as internal staff turmoil. The role has since been temporarily filled by Deputy Commissioner for Food Kyle Diamantas, who insisted that he was pro-life amid concerns about a past assignment representing Planned Parenthood in a property dispute.

In August, President Donald Trump announced as his permanent choice Overton, currently deputy director of the White House Domestic Policy Council, who served on the president’s Office of American Innovation and Domestic Policy Council in Trump’s first term.

Overton was initially met with optimism from pro-lifers, but in September questioning declined to reaffirm her past comments recognizing the danger of abortion pills, raising concerns about an issue on which the Trump administration was already facing pro-life discontent for slow-walking the restoration of rules that had been waived by the Biden administration.

On Tuesday, an administration official told Axios that Overton’s nomination has been pulled because she “lacks the support on the Hill to move forward with her confirmation.”

NBC News adds that crucial votes such as Sens. Bill Cassidy (R-LA), Susan Collins (R-ME), and Lisa Murkowski (R-AK) were still undecided as of last week, with Collins saying she still needed “to get some answers on various things.” Reporting cites doubts about Overton’s commitment to the pro-life and so-called “Make America Healthy Again” causes, as did questions about her experience level. 

But following her withdrawal, Cassidy suggested deeper issues between the administration and pro-lifers were ultimately to blame.

“Tonight, the White House abandoned a viable confirmation path for Dr. Overton,” Cassidy wrote on X. “The WH said that this was because she did not have the votes to pass. This was odd as I was having productive conversations with members. I believe she would have had the votes to pass out of committee and pass the full Senate. My conversations with her convinced me she would follow the science and push back against decisions that put Americans’ health at risk.”

“The last issue was that pro-life Senators sought final assurances from the Administration regarding the Administration’s commitment to life issues,” he continued. “The Administration withdrew Dr. Overton rather than make such commitments. Unfortunately, with the limited time left, confirming a permanent FDA Commissioner will fall to Senate Democrats.”-\

In May 2025, the Trump administration promised a “complete review” of abortion pill safety data that pro-lifers hope might lead to a restoration of pre-Biden restrictions, but more than a year came and went without results while the administration resisted pro-life lawsuits to force an immediate rule change. 

Last month, the FDA said it now expected the review to be complete by May 2027, feeding longstanding suspicions that the results were being delayed until after the midterm elections. However, any resulting pro-life policy change could still take until the final months of Trump’s presidency.

Read Entire Article